Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 1
2013 1
2014 7
2015 12
2016 8
2017 5
2018 2
2019 1
2020 1
2021 8
2022 8
2023 11
2024 10
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Özgüroğlu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS; LAURA Trial Investigators. Lu S, et al. N Engl J Med. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828946 Clinical Trial.
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
Shitara K, Lorenzen S, Li J, Bai Y, Fernández MG, Aguilar M, Shoji H, Reyes-Cosmelli F, Peña YR, Corrales L, Wyrwicz L, Eyzaguirre DA, Pan Y, Ryu MH, Cohen DJ, Wainberg ZA, Ku G, Tabernero J, Van Cutsem E, Qin SK, Oh DY, Xu J, Liang LW, Bordia S, Bhagia P, Rha SY; LEAP-015 Investigators. Shitara K, et al. J Clin Oncol. 2025 Aug;43(22):2502-2514. doi: 10.1200/JCO-25-00748. Epub 2025 May 31. J Clin Oncol. 2025. PMID: 40448579 Free PMC article. Clinical Trial.
Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study.
Şenocak Taşçı E, Mutlu AU, Saylık O, Ölmez ÖF, Bilici A, Sünger E, Sütçüoğlu O, Çakmak Öksüzoğlu ÖB, Özdemir N, Akdoğan O, Bayoğlu İV, Majidova N, Güren AK, Özen Engin E, Hacıbekiroğlu İ, Er Ö, Dane F, Bozkurt M, Turan Canbaz E, Erdamar S, Aytaç E, Özer L, Yıldız İ. Şenocak Taşçı E, et al. Among authors: hacibekiroglu i. Cancers (Basel). 2024 Sep 21;16(18):3213. doi: 10.3390/cancers16183213. Cancers (Basel). 2024. PMID: 39335184 Free PMC article.
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.
Kahraman S, Erul E, Gumusay O, Guven DC, Aksoy S, Basaran G, Seyyar M, Sahin E, Cabuk D, Bayram E, Paydas S, Demirel BC, Yaren A, Gulbagci B, Hacibekiroglu I, Baytemur NK, Demirci U, Davarci SE, Demir H, Mocan EE, Dogan O, Cilbir E, Yasar A, Bayoglu IV, Hizal M, Kayikcioglu E, Cetin B, Acar O, Erdogan AP, Keskinkilic M, Yavuzsen T, Unal OU, Yilmaz F, Dogan M, Orhan SO, Cubukcu E, Erol C, Sakalar T, Dulgar O, Karakas Y, Ozkanli G, Duman BB, Isik D, Karaoglanoglu M, Okutur SK, Yildirim N, Aydin E, Uluc BO, Keser M, Bilgin B, Aksoy A, Eren O, Kalkan NO, Er MM, Yucel H, Sunar V, Paksoy N, Aydin D, Turhal NS, Menekse S, Kut E, Aykan MB, Ozdemir O, Ozcelik M, Iriagac Y, Selcukbiricik F, Inal A, Karadurmus N, Akinci MB, Sendur MAN. Kahraman S, et al. Among authors: hacibekiroglu i. Clin Breast Cancer. 2025 Jul;25(5):e635-e644. doi: 10.1016/j.clbc.2025.03.003. Epub 2025 Mar 4. Clin Breast Cancer. 2025. PMID: 40190010
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
Özyurt N, Alkan A, Gülbağcı B, Seyyar M, Aşık E, Şahbazlar M, Türker M, Kınıkoğlu O, Yerlikaya T, Dinç G, Aytaç A, Kalkan Z, Ebinç S, Gültürk İ, Keskinkılıç M, İşleyen ZS, Çağlayan D, Türkel A, Aydın E, Şakalar T, Sekmek S, Yıldırım N, Koçak S, Okutur K, Özveren A, Dursun B, Kitaplı S, Eren OÖ, Beypınar İ, Hacıbekiroğlu İ, Çabuk D, Karaman E, Acar Ö, Paydaş S, Eryılmaz MK, Demir B, Oruç Z, Yılmaz M, Biricik FS, Salim DK, Tanrıverdi Ö, Doğan M. Özyurt N, et al. Among authors: hacibekiroglu i. Sci Rep. 2024 Oct 9;14(1):23556. doi: 10.1038/s41598-024-75293-5. Sci Rep. 2024. PMID: 39384975 Free PMC article.
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.
Şahin G, Tüzün EK, Güzel HG, Guliyev M, Dişli AK, Yazıcı M, Yıldız O, Güneş TK, Alkan S, Kahraman EG, Özel GS, İçli MC, Şahin E, Muğlu H, Acar C, Tunbekici S, Yüksel HÇ, Yücel H, Kahya BU, Kitaplı S, Büyükşimşek M, İpek ŞA, Dama PE, Usta EA, Yılmaz M, Aşık E, Özalp FR, Savsar MG, Kocaaslan E, Sim S, Ağaoğlu AB, Çamöz ES, Demir T, Uyar GC, Yıldırım A, Çınkır HY, Salim DK, Doğu GG, Alan Ö, Bayram E, Karaçin C, Güç ZG, Ekinci F, Eryılmaz MK, Semiz HS, Ünal OÜ, Göksu SS, Öztürk B, İnanç M, Uygun K, Hacıbekiroğlu İ, Erçolak V, Kara İO, Yazıcı O, Bilici A, Tanrıverdi Ö, Karaca B, Erman M, Gökmen E, Göker E, Yıldırım HÇ. Şahin G, et al. Among authors: hacibekiroglu i. Int J Cancer. 2025 Sep 19. doi: 10.1002/ijc.70165. Online ahead of print. Int J Cancer. 2025. PMID: 40968962
Major and minor salivary gland cancers: A multicenter retrospective study.
Hacioglu MB, Erdogan B, Bardakcı M, Algın E, Gulbagcı B, Hacibekiroglu I, Hamdard J, Olmez OF, Akkus H, Oksuzoglu B, Goksu SS, Dae SA, Sumbul AT, Ugraklı M, Karaagac M, Sahin E, Cabuk D, Ozer O, Yavuzsen T, Arıkan R, Köstek O, Atcı MM, Sakin A, Deligonul A, Bayır D, Dincer M, Unsal O, Yazıcı O, Zeynelgil E, Gulmez A, Harputluoglu H, Erol C, Sendur MAN, Aytekin A, Akagunduz B, Oner I, Er O, Oztosun B, Gumus M, Selçukbiricik F, Aykan MB, Karadurmus N, Degerli E, Demirci NS, Turkmen E, Şakalar T, Secmeler S, Tanrıverdi O, Alkan A, Kemal Y, Cil I, Unal C, Iriagaç Y, Alan O, Balli S, Urun Y, Ozcan E, Turhal NS, Cicin I. Hacioglu MB, et al. Among authors: hacibekiroglu i. Head Neck. 2023 Jul;45(7):1643-1653. doi: 10.1002/hed.27376. Epub 2023 Apr 21. Head Neck. 2023. PMID: 37084179
83 results